PANOVISION: Feasibility and Safety of Hybrid IVUS-OCT System

Last updated: February 10, 2023
Sponsor: Harbin Medical University
Overall Status: Completed

Phase

N/A

Condition

Hypercholesterolemia

Thrombosis

Chest Pain

Treatment

N/A

Clinical Study ID

NCT05596279
VP-3003-1901
  • Ages 18-75
  • All Genders

Study Summary

Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) were all recommended for percutaneous coronary intervention (PCI) optimization in the latest guidelines, however, which imaging modality was more suitable as either a diagnostic or guidance tool was still unknown. Recently, a novel, well-designed hybrid imaging system was approved for clinical use, allowing the accurate co-registration of two imaging modalities and immediate, simultaneous image review. For testing each modality in the hybrid imaging system, the investigators conducted this prospective, multicentre, non-inferiority trial. In this study, all participants achieved hybrid IVUS-OCT imaging after stenting, at meanwhile, patients randomly assigned to the IVUS arm were performed control IVUS (OptiCross, Boston Scientific, Natick, MA), and patients randomly assigned to the OCT arm were performed control OCT (C7 Dragonfly Duo, St. Jude Medical, St. Paul, MN). In this study, the investigators evaluated the non-inferiority of standalone IVUS versus control IVUS or standalone OCT versus control OCT in clinical feasibility using clear stent capture rate (CSCR) and safety using perioperative device-related adverse cardiovascular events.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18-75 years
  • Patients eligible for elective percutaneous coronary intervention
  • Understand and voluntarily sign the informed consent form

Exclusion

Exclusion Criteria: The lesion-related exclusion criteria:

  • More than 1 stent was planned to deploy in culprit lesion
  • In-stent restenosis
  • Bifurcation lesion with proposed double stent implantation
  • The length of the reference vessel segment proximal or distal to the lesion was lessthan 5mm
  • The length of the implanted stent was larger than 33mm
  • The diameter of reference vessel was less than 2 mm or larger than 4 mm
  • Lesions were in left main or ostium of right coronary artery
  • The distance between either end of the lesion and the lateral branches larger than 2mm in diameter was less than 5 mm
  • Angiography revealed thrombosis in culprit vessel
  • Severely calcified lesions or tortuous coronary arteries
  • Decreased blood flow (thrombolysis in myocardial infarction score ≤ 2) Patients-level exclusion criteria:
  • Breastfeeding or pregnant women, the subject (or his partner) who had a pregnancy planduring the trial or within 6 months after the end of the trial, and subject who didnot agree to use contraception during the trial
  • Participants who had withdrawn from other clinical studies within 3 months or areparticipating in other clinical trials
  • Acute myocardial infarction occurred within one week prior to screening
  • Cardiac troponin I or cardiac troponin T levels exceed the upper limit of normalreference values within 72 hours of procedure and were of clinical significance
  • Renal insufficiency with creatinine > 200μmol/L
  • Unsuitable for coronary artery bypass grafting (CABG)
  • Unsuitable for percutaneous coronary intervention;
  • Coronary spasm
  • Chronic total occlusion or subtotal occlusion
  • Severe hemodynamic disturbances or shock
  • History of CABG
  • Coagulation is abnormal and clinically significant
  • Severe heart failure (NYHA III, IV or Left ventricular ejection fraction < 30%)
  • History of contrast allergy
  • Multi-vessel disease
  • Chemotherapy or planned chemotherapy
  • Investigators consider unsuitable for participants selected for this study

Study Design

Total Participants: 100
Study Start date:
November 20, 2019
Estimated Completion Date:
July 30, 2021

Connect with a study center

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang 150086
    China

    Site Not Available

  • Wuhan Asia Heart Hospital

    Wuhan, Hubei 430010
    China

    Site Not Available

  • The Second Hospital of Jilin University

    Changchun, Jilin 150056
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.